157 related articles for article (PubMed ID: 28186982)
1. AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies.
Milazzo FM; Anastasi AM; Chiapparino C; Rosi A; Leoni B; Vesci L; Petronzelli F; De Santis R
Oncotarget; 2017 Apr; 8(14):22590-22605. PubMed ID: 28186982
[TBL] [Abstract][Full Text] [Related]
2. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
[TBL] [Abstract][Full Text] [Related]
3. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
[TBL] [Abstract][Full Text] [Related]
5. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative.
Minenkova O; Vesci L; De Santis R; Santapaola D; Cincinelli R; Musso L; Dallavalle S; Giannini G
Bioorg Med Chem Lett; 2018 Nov; 28(20):3312-3314. PubMed ID: 30243588
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab.
De Santis R; Rosi A; Anastasi AM; Chiapparino C; Albertoni C; Leoni B; Pelliccia A; Santapaola D; Carollo V; Marra E; Aurisicchio L; Arseni B; Pacello ML; Palmieri G; Battella S; Petronzelli F; Milazzo FM
Oncotarget; 2014 Oct; 5(19):9239-55. PubMed ID: 25238453
[TBL] [Abstract][Full Text] [Related]
8. AvidinOX™ for tissue targeted delivery of biotinylated cells.
Nucera E; Nicoletti C; Chiapparino C; Pacello ML; D'Alessio V; Musarò A; De Santis R
Int J Immunopathol Pharmacol; 2012; 25(1):239-46. PubMed ID: 22507336
[TBL] [Abstract][Full Text] [Related]
9. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.
Zheng L; Tan W; Zhang J; Yuan D; Yang J; Liu H
Cancer Immunol Immunother; 2014 Jun; 63(6):581-6. PubMed ID: 24668364
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
11. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
[TBL] [Abstract][Full Text] [Related]
12. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
15. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
16. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
17. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
[TBL] [Abstract][Full Text] [Related]
18. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells--preliminary study.
Uberall I; Krízová K; Steigerová J
Klin Onkol; 2011; 24(5):356-60. PubMed ID: 22070017
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]